{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:58:34Z","timestamp":1787068714810,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","seminarsinnephrology.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.semnephrol.2017.05.019","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T04:15:16Z","timestamp":1503980116000},"page":"464-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunosuppression in IgA Nephropathy: Guideline Medicine Versus Personalized Medicine"],"prefix":"10.1016","volume":"37","author":[{"given":"John","family":"Feehally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2017.05.019_bib1","first-page":"694","article-title":"Les d\u00e9p\u00f4ts intercapillaire d\u2019IgA-IgG","volume":"74","author":"Berger","year":"1968","journal-title":"J Urol Nephrol (Paris)"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.semnephrol.2007.10.004","article-title":"Secondary IgAN JB Secondary IgA nephropathy","volume":"28","author":"Pouria","year":"2008","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib3","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","article-title":"Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population","volume":"27","author":"Le","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000382134","article-title":"New insights into the pathogenesis of IgA nephropathy","volume":"1","author":"Novak","year":"2015","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib5","first-page":"1","article-title":"KDIGO Clinical Practice Guideline for Glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib6","unstructured":"Evidence based clinical practice guidelines for IgA nephropathy 2014. [cited 2016 August 19]. Available from: www.jsn.or.jp\/en\/guideline\/pdf\/IgA_eng.pdf."},{"key":"10.1016\/j.semnephrol.2017.05.019_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ndt\/9.supp.23","article-title":"Strategies for the management of IgA nephropathy","author":"Feehally","year":"1994","journal-title":"International year book of nephrology dialysis transplantation"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib8","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.ajkd.2012.02.326","article-title":"Risk stratification of patients with IgA nephropathy","volume":"59","author":"Barbour","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib10","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.2015.322","article-title":"The MEST score provides earlier risk prediction in lgA nephropathy","volume":"89","author":"Barbour","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000364954","article-title":"Long-term outcome of IgA nephropathy patients with recurrent macroscopic hematuria","volume":"40","author":"Le","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib13","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/ndt\/gfq553","article-title":"Normoalbuminaemia is associated with IgA nephropathy in primary glomerulopathy with nephrotic-range proteinuria in Chinese patients","volume":"26","author":"Chen","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5414\/CNP65203","article-title":"Mesangial IgA deposition in minimal change nephrotic syndrome: coincidence of different entities or variant of minimal change disease?","volume":"65","author":"Westhoff","year":"2006","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib15","first-page":"1033","article-title":"Corticosteroid therapy in IgA nephropathy with minimal change-like lesions: a single-centre cohort study","volume":"9","author":"Wang","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2215\/CJN.11951113","article-title":"IgA nephropathy with minimal change disease","volume":"9","author":"Herlitz","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib17","first-page":"174","article-title":"Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial","volume":"26","author":"Lai","year":"1986","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib18","first-page":"37","article-title":"Participation of extracapillary lesions (ECL) in progression of IgA nephropathy","volume":"25","author":"Abe","year":"1986","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib19","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ndt\/gfg081","article-title":"Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide","volume":"18","author":"Tumlin","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib20","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1681\/ASN.2012101017","article-title":"Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study","volume":"24","author":"Lv","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1053\/ajkd.2000.17615","article-title":"ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits","volume":"36","author":"Haas","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib22","first-page":"482","article-title":"Clinical features of IgA nephropathy with serum ANCA positivity: a retrospective case-control study. Clin","volume":"8","author":"Yang","year":"2015","journal-title":"Kidney J"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40620-015-0227-8","article-title":"Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression","volume":"29","author":"Chakera","year":"2016","journal-title":"J Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: a randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib25","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","article-title":"Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial","volume":"53","author":"Lv","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib27","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/j.ajkd.2016.03.001","article-title":"Should immunosuppressive therapy be used in slowly progressive IgA nephropathy?","volume":"68","author":"Feehally","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib29","series-title":"The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study. Late breaking trials abstract","author":"Lv","year":"2016"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib30","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstr\u00f6m","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib31","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study","volume":"26","author":"Tesar","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib32","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2215\/CJN.02300215","article-title":"Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy","volume":"11","author":"Sarcina","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2169\/internalmedicine.53.1136","article-title":"Comparison of glucocorticoids alone and combined with cyclosporine a in patients with IgA nephropathy: a prospective randomized controlled trial","volume":"53","author":"Liu","year":"2014","journal-title":"Intern Med"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib34","doi-asserted-by":"crossref","first-page":"e71545","DOI":"10.1371\/journal.pone.0071545","article-title":"Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib35","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib36","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib37","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib38","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ki.2009.499","article-title":"Long-term study of mycophenolate mofetil treatment in IgA nephropathy","volume":"77","author":"Tang","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.kjms.2014.10.004","article-title":"Severe pneumonia in mycophenolate mofetil combined with low-dose corticosteroids-treated patients with immunoglobulin A nephropathy","volume":"31","author":"Wan","year":"2015","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib40","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib41","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib42","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1046\/j.1523-1755.2003.00935.x","article-title":"The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy","volume":"63","author":"Xie","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib43","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2215\/CJN.00310108","article-title":"Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study","volume":"3","author":"Komatsu","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000441852","article-title":"Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy","volume":"132","author":"Feehally","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib45","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/ndt\/gfu020","article-title":"A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy","volume":"29","author":"Kawamura","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib46","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1053\/j.ajkd.2013.04.021","article-title":"Evaluation of the Oxford classification of IgA nephropathy: a systematic review and meta-analysis","volume":"62","author":"Lv","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib47","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.2215\/CJN.02890311","article-title":"Validation study of Oxford classification of IgA nephropathy: the significance of extracapillary proliferation","volume":"6","author":"Katafuchi","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib48","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1681\/ASN.2016040433","article-title":"Predictive value of crescents in IgA nephropathy - a multicenter study","volume":"28","author":"Haas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib49","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2017.05.019_bib50","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027092951730058X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027092951730058X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T04:23:38Z","timestamp":1535430218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027092951730058X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S027092951730058X"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2017.05.019","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppression in IgA Nephropathy: Guideline Medicine Versus Personalized Medicine","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2017.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}